Market Research Logo

Diagnostics and Therapeutics for HIV: Global Markets

Diagnostics and Therapeutics for HIV: Global Markets

Report Scope:

This report organizes information from diverse sources into sections, including an overview, industry structure, diagnostic test type, treatment by drug categories, leading drug profiles and historic drug sales, regulations, reimbursements and patents. The scope of this report includes an overview of the global market scenario for diagnosis and treatments of HIV, with base year data from 2017, estimations for 2018 and forecasts for 2023 using projections of CAGR during the forecast period. Market data in terms of value is provided at global, regional and country levels for treatments by drug categories. Market data for HIV diagnostics is provided for regional levels, with details on test types. Estimated values are based on companies’ total revenues. Projected and forecasted revenue values are in constant U.S. dollars, unadjusted for inflation.

The report forecasts the global market for HIV therapeutics by drug class and discusses market data for nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), protease inhibitors (PIs), single tablet regimen fixed-dose combination (STR FDC), HIV integrase stand transfer inhibitors (INSTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs). The enzyme inhibitor drug class has been excluded when calculating the global HIV therapeutics market, as there are no late-stage pipeline molecules.

Diagnostic tests such as antigen- and antibody-based tests, CD4 tests and viral load tests are detailed with current and forecasted market data. Antigen- and antibody-based tests cover enzyme-linked immunosorbent assay (ELISA) tests, enzyme immunoassay (EIA) tests, rapid tests and NAT tests; CD4 tests include tests conducted to monitor the CD4 load; and viral load tests include all PCR-based tests.

Market dynamics, such as trends and challenges, are discussed in the report. This report also involves regional market overviews for North America, Europe, Asia-Pacific and Rest of the World. The regional overviews provide information on the epidemiology of HIV by country and region and details market data for each region. The regulatory scenario is discussed for the United States, Europe and Japan to provide an overview of the regulations for new drug launches and diagnostic kits. The reimbursement scenario is outlined for the United States, Europe and Japan to provide an overview to readers of this report. The pipeline analysis chapter discusses four major drug categories to provide details on major pipeline developments. The competitive landscape discusses the major manufacturers involved in the HIV therapeutics market, key developments and product offerings.

Report Includes:

- 37 data tables and 49 additional tables
- Industry analysis of diagnostics and therapeutics for the HIV disease, and its global markets
- Analyses of global market trends with data from 2017, estimates for 2018, and projections of compound annual growth rates (CAGRs) through 2023
- Characterization and quantification of market potential for therapeutic drugs for HIV virus by drug categories, diagnostic test types, application sectors and geographical regions
- Country-specific data and analysis for United States, Canada, Mexico, Japan, China, India, France, Germany, U.K., Italy, Spain and Middle East and Africa
- Evaluation of the market dynamics such as drivers, restraints and current industry trends and patterns
- Discussion of the regulatory scenario for United States, Europe, and Japan to provide an overview of the regulations for new drug launches and diagnostic kits
- Examination of cost implications for treatments across a range of countries
- A look at ongoing research and the future direction of the market
- Assessment of the competitive landscape and discussion of the major manufacturers involved in the HIV therapeutics market, key developments and product offerings, including Abbott Laboratories, Bio-Rad Laboratories, Cipla Inc., GlaxoSmithKline, Merck & Co., Siemens Healthineers and Thermo Fisher Scientific


Chapter 1 Introduction
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports
Chapter 2 Summary and Highlights
Chapter 3 Overview
Overview of Human Immunodeficiency Virus (HIV)
Report Overview
Disease Prognosis
Symptoms
Treatments
HIV Timeline and Milestones
HIV Life Cycle: Treatment and Mechanism of Action
HIV Prophylaxis
Pre-exposure Prophylaxis (PrEP)
Post-exposure Prophylaxis (PEP)
Drug Resistance
Medication Adherence
WHO Initiatives
Chapter 4 Global Industry Trends
Trends in Global HIV Transmission
Regional Awareness Programs
Development of Novel Therapies
Public-Private Partnerships
Rising Comorbidities in HIV Patients with an Increase in the Longevity of Patients
Global Programs to Counter HIV
Preventing Transmission from Mother to Child
Challenges
Underestimating the Risk of Contracting the Disease
Social Stigma Associated with STDs
High Cost of Treatment
Chapter 5 Global HIV Therapeutics Market
Global HIV Therapeutics Market and Forecast Overview
North American HIV Therapeutics Market
Epidemiology
HIV Testing and Recommendations
Regulations Impacting the North American HIV Therapeutics Market
Market Analysis and Forecast
European HIV Therapeutics Market
Epidemiology
HIV Testing and Recommendations
Regulations Impacting the European HIV Market
Market Analysis and Forecast
Asia-Pacific HIV Therapeutics Market
Epidemiology
Prevention and Screening Programs
Regulations Impacting the Asia-Pacific HIV Market
Market Impact of Generic Manufacturers
Market Analysis and Forecast
Rest of World (RoW) HIV Therapeutics Market
Epidemiology
Market Analysis and Forecast
Global Investments in HIV Market
Chapter 6 HIV Therapeutics Market by ARV Drug Categories
Timeline of Therapies
First-Line Treatment Regimen
Second-line Treatment Regimen
Third-line/Salvage Treatment Regimen
Market Overview by Drug Category
Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs)
Protease Inhibitors (PIs)
Single-Tablet Regimen (STR)/Fixed-Dose Combination (FDC) Drugs
Integrase Strand Transfer Inhibitors (INSTI)
Non-nucleotide Reverse Transcriptase Inhibitors (NNRTIs)
Entry Inhibitors
Chapter 7 Leading Drugs in the HIV Therapeutics Market
Leading HIV Drugs
Drug Profiles
Genvoya
Triumeq
Truvada
Tivicay (Dolutegravir)
Prezista/Prezcobix/Rezolsta/Symtuza
Atripla
Descovy
Isentress/Isentress HD
Odefsey
Stribild
Eviplera
Viread
Promising Emerging Therapies
Darunavir/Cobicistat/FTC/TAF Fixed-dose Combination
Biktarvy (Bictegravir, Emtricitabine, Tenofovir Alafenamide)
Ibalizumab (Trogarzo)
Estimated Drug Revenue Forecast
Genvoya
Triumeq and Tivicay
Odefsey
Stribild
Chapter 8 HIV Diagnostics Market
HIV Diagnostics Market by Test Type
Evolution of HIV Tests
Antigen- and Antibody-Based Tests
Future Perspective
CD4 Testing
Future Perspective
Viral Load Testing
Future Perspective
HIV Diagnostics Product Profiles by Test Type
CD4 Testing Products
Viral Load Testing Products
Chapter 9 Pipeline Analysis
HIV Pipeline Overview
Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs) Drugs in Development
NNRTI Drugs in Development
Doravirine/TDF/3TC
Other Categories
Generic Dolutegravir (Integrase Inhibitors)
Albuvirtide (Aikening) (Fusion inhibitors)
Juluca (Dolutegravir/Rilpivirine)
Isentress HD (Raltegravir) (Integrase Inhibitors)
Combination Therapies
Approved and Tentatively Approved Antiretrovirals
Chapter 10 Regulatory and Reimbursement Structure
Overview of Regulations
United States
Europe
Japan
China
Overview of Pricing and Reimbursement
United States
Europe
Japan
Chapter 11 Competitive Landscape and Key Developments
Market Share Analysis
Patent Analysis
Key Developments
Chapter 12 Company Profiles
ABBOTT LABORATORIES
Company Overview
Product Information
Development and Strategies
Financials
ABBVIE INC.
Company Overview
Financials
AGILENT TECHNOLOGIES INC.
Company Overview
Product Information
Financials
AUROBINDO PHARMA LTD.
Company Overview
BECTON, DICKINSON AND CO.
Company Overview
Product Information
Key Developments and Strategies
Financials
BIOMERIEUX INC.
Company Overview
BIO-RAD LABORATORIES INC.
Company Overview
Product Overview
BRISTOL-MYERS SQUIBB CO.
Company Overview
Product Information
Financials
CEPHEID INC.
Company Overview
CIPLA INC.
Company Overview
GILEAD SCIENCES INC.
Company Overview
Product Information
Development and Strategies
Financials
GLAXOSMITHKLINE PLC
Company Overview
Development and Strategies
Financials
HOFFMANN-LA ROCHE INC.
Company Overview
Product Information
HOLOGIC INC.
Company Overview
Product Overview
JANSSEN PHARMACEUTICALS INC.
Company Overview
Product Information
Developments and Strategies
Financials
MERCK & CO. INC.
Company Overview
Product Information
Development and Strategies
Financials
MERIDIAN LIFE SCIENCE INC.
Company Overview
MYLAN LABORATORIES
Company Overview
Product Information
Development and Strategies
Financials
SIEMENS HEALTHINEERS
Company Overview
Product Overview
THERMO FISHER SCIENTIFIC INC.
Company Overview
VIIV HEALTHCARE
Company Overview
Product Information
Chapter 13 Appendix: Abbreviations and Glossary
Abbreviations
Glossary of Terms
List of Tables
Summary Table : Global Market for HIV Therapeutics, by Drug Category, Through 2023
Table 1 : Milestones in the History of HIV
Table 2 : Life Cycle of HIV Therapeutics Target Points
Table 3 : ART Therapy Coverage, by Region, 2017
Table 4 : Global Market for HIV Therapeutics, by Region, Through 2023
Table 5 : Global Market for HIV Therapeutics, by Drug Category, Through 2023
Table 6 : North American Market for HIV Therapeutics, by Drug Category, Through 2023
Table 7 : European Incidence of HIV, 2014-2016
Table 8 : European AIDS Diagnosis, by Country, 2014-2016
Table 9 : European AIDS-related Mortality, by Country, 2014-2016
Table 10 : HIV Tests Performed in Europe, by Country, 2014-2016
Table 11 : European ART Therapy Coverage, by Country, 2017
Table 12 : European Market for HIV Therapeutics, by Drug Category, Through 2023
Table 13 : Asia-Pacific Incidence and Prevalence of HIV, by Country, 2016 and 2017
Table 14 : Generic Drug Manufacturers in the Asia-Pacific Region
Table 15 : Asia-Pacific Market for HIV Therapeutics, by Drug Category, Through 2023
Table 16 : South America, Middle East and Africa HIV/AIDS Epidemiology, by Region, 2016
Table 17 : Rest of World Market for HIV Therapeutics, by Drug Category, Through 2023
Table 18 : Investments on R&D for HIV Cure, by Country, 2012-2016
Table 19 : Top 20 Private Funders of HIV/AIDS, 2016
Table 20 : Recommendations of ART Treatment, by WHO, 2016
Table 21 : Approved NRTIs
Table 22 : Approved Generic NRTIs
Table 23 : Global Market for NRTIs, by Region, Through 2023
Table 24 : Approved PIs
Table 25 : Approved Generic PIs
Table 26 : Pharmacokinetic Enhancers, 2017
Table 27 : Global Market for Protease Inhibitors, by Region, Through 2023
Table 28 : Approved STRs
Table 29 : Approved STR FDC Generics
Table 30 : Global Market for Single-tablet Regimen FDC, by Region, Through 2023
Table 31 : FDA Approved INSTIs
Table 32 : Global Market for INSTIs, by Region, Through 2023
Table 33 : Approved NNRTIs
Table 34 : Approved Generic NNRTIs
Table 35 : Global Market for NNRTIs, by Region, Through 2023
Table 36 : Approved Entry Inhibitors
Table 37 : Historic Sales of Leading HIV Drugs, 2015-2017
Table 38 : Historic Sales and Estimated Revenue Forecast of Leading HIV Drugs, Through 2023
Table 39 : Approved Products, Regulatory Agency
Table 40 : Global Market for HIV Diagnostics, by Region, Through 2023
Table 41 : Global Market for HIV Diagnostics, by Test Type, Through 2023
Table 42 : Antibody HIV Tests
Table 43 : FDA Approved Antigen-Antibody Combo Tests
Table 44 : Point-of-care CD4 Tests
Table 45 : Viral Load Tests, 2013
Table 46 : Viral Load Tests, 2015
Table 47 : NRTI Pipeline, 2018
Table 48 : NRTIs Recently Approved, 2018
Table 49 : NNRTIs, 2018
Table 50 : Other Drug Classes in Development, 2018
Table 51 : Combination Therapies in Development, 2018
Table 52 : Antiretrovirals Approved and Tentatively Approved by FDA in Association with President’s Emergency Plan, 2015-2018
Table 53 : Preventive Health Services for Children Covered by Private Plans Without Cost Sharing
Table 54 : Gilead Sciences: Leading Products Revenue, 2015-2017
Table 55 : GlaxoSmithKline: Leading Products Revenue, 2015-2017
Table 56 : Johnson & Johnson: Leading Products Revenue, 2015-2017
Table 57 : Company Market Shares of HIV Therapeutics
Table 58 : Key U.S. Patents on HIV Diagnostics and Therapeutics
Table 59 : Key U.S Patents on Blockbuster HIV/AIDS Drugs
Table 60 : Key Developments in the HIV Market, 2016-2018
Table 61 : Abbott Laboratories: Marketed Products and Therapeutics
Table 62 : Abbott Laboratories: Marketed Products and Diagnostics
Table 63 : Abbott Laboratories: Revenue, 2015-2017
Table 64 : AbbVie: Net Revenue, 2015-2017
Table 65 : Agilent Technologies: Marketed Products and Diagnostics
Table 66 : Agilent Technologies: Revenue, 2015-2017
Table 67 : Becton, Dickinson and Co.: Marketed Products
Table 68 : Bio-Rad Laboratories: Marketed Products and Diagnostics
Table 69 : Bristol-Myers Squibb: Marketed Products
Table 70 : Bristol-Myers Squibb: Net Revenue, 2015-2017
Table 71 : Gilead Science: Marketed Products
Table 72 : Gilead Sciences: Net Revenue, 2015-2017
Table 73 : GlaxoSmithKline: Net Revenue, 2014-2016
Table 74 : Hoffmann-La Roche Inc.: Marketed Products, Diagnostics
Table 75 : Hologic: Marketed Products, Diagnostics
Table 76 : Janssen Pharmaceuticals: Marketed Products
Table 77 : Johnson & Johnson: Net Revenue, 2014-2016
Table 78 : Merck & Co.: Marketed Products
Table 79 : Merck & Co.: Net Revenue, 2014-2016
Table 80 : Mylan Laboratories: Marketed Products
Table 81 : Mylan: Net Revenue, 2015-2017
Table 82 : Siemens Healthineers: Marketed Products, Diagnostics
Table 83 : ViiV Healthcare Group of Companies: Marketed Products
Table 84 : Abbreviations in Diagnostics and Therapeutics for HIV
Table 85 : Glossary of Terms
List of Figures
Summary Figure : Global Market for HIV Therapeutics, by Drug Category, 2017-2023
Figure 1 : Types of Drug Failure Encountered During HIV Treatment
Figure 2 : Global Prevalence of HIV, by Region, 2016
Figure 3 : Global Incidence of HIV, by Region, 2016
Figure 4 : Global Market for HIV Therapeutics, 2017-2023
Figure 5 : Global HIV Therapeutics Market Share, by Region, 2017
Figure 6 : Global HIV Therapeutics Market Share, by Region, 2023
Figure 7 : Global HIV Therapeutic Market Share, by Drug Category, 2017
Figure 8 : Global HIV Therapeutics Market Share, by Drug Category, 2023
Figure 9 : North American Market for HIV Therapeutics, 2017-2023
Figure 10 : U.S. Historic and Current Incidence of HIV, 2011-2016
Figure 11 : Canadian Historic and Current Incidence of HIV, 2011-2016
Figure 12 : North American HIV Therapeutics Market Share, by Drug Category, 2017
Figure 13 : North American HIV Therapeutics Market Share, by Drug Category, 2023
Figure 14 : North American Market for HIV Therapeutics, by Country, 2017-2023
Figure 15 : North American HIV Therapeutics Market Share, by Country, 2017
Figure 16 : North American HIV Therapeutics Market Share, by Country, 2023
Figure 17 : European Market for HIV Therapeutics, 2017-2023
Figure 18 : U.K. Incidence of HIV Among Gay and Bisexual Men, 2015 and 2016
Figure 19 : European HIV Therapeutics Market Share, by Drug Category, 2017
Figure 20 : European HIV Therapeutics Market Share, by Drug Category, 2023
Figure 21 : European Market for HIV Therapeutics, by Country, 2017-2023
Figure 22 : European HIV Therapeutics Market Share, by Country, 2017
Figure 23 : European HIV Therapeutics Market Share, by Country, 2023
Figure 24 : HIV Transmission Share in Australia, by Mode, 2015
Figure 25 : Asia-Pacific Market for HIV Therapeutics, 2017-2023
Figure 26 : India's Historic and Current Incidence of HIV, 2005-2016
Figure 27 : India's Historic and Current Prevalence of HIV, 2005-2016
Figure 28 : India's Historic and Current AIDS Mortality, 2005-2016
Figure 29 : South Korea's Historic and Current Incidence of HIV/AIDS Infection, 2001-2016
Figure 30 : Australia's Historic and Current Incidence of HIV, 2012-2015
Figure 31 : Singapore's Historic and Current Incidence of HIV/AIDS Infections, 2001-2016
Figure 32 : Asia-Pacific HIV Therapeutics Market Share, by Drug Category, 2017
Figure 33 : Asia-Pacific HIV Therapeutics Market Share, by Drug Category, 2023
Figure 34 : Asia-Pacific Market for HIV Therapeutics, by Country, 2017-2023
Figure 35 : Asia-Pacific HIV Therapeutics Market Share, by Country, 2017
Figure 36 : Asia-Pacific HIV Therapeutics Market Share, by Country, 2023
Figure 37 : Rest of World Market for HIV Therapeutics, 2017-2023
Figure 38 : Rest of World HIV Therapeutics Market Share, by Drug Category, 2017
Figure 39 : Rest of World HIV Therapeutics Market Share, by Drug Category, 2023
Figure 40 : NIH Investments in HIV Research, 2014-2016
Figure 41 : Private Philanthropic Disbursements for HIV/AIDS, 2007-2016
Figure 42 : Treatment Switching
Figure 43 : Global Market for NRTIs, 2017-2023
Figure 44 : Global Market for NRTIs, by Region, 2017-2023
Figure 45 : Global Market for Protease Inhibitors, 2017-2023
Figure 46 : Global Market for Protease Inhibitors, by Region, 2017-2023
Figure 47 : Global Market for Single-tablet Regimen FDC, 2017-2023
Figure 48 : Global Market for Single-tablet Regimen FDC, by Region, 2017-2023
Figure 49 : Global Market for INSTIs, 2017-2023
Figure 50 : Global Market for INSTIs, by Region, 2017-2023
Figure 51 : Global Market for NNRTIs, 2017-2023
Figure 52 : Global Market for NNRTIs, by Region, 2017-2023
Figure 53 : HIV Diagnostics Test Types, by Category
Figure 54 : Global Market for HIV Diagnostics, 2017-2023
Figure 55 : Global Market for HIV Diagnostics, by Region, 2017-2023
Figure 56 : Global Market for Antigen- and Antibody-based Tests, 2017-2023
Figure 57 : Global Market for CD4 Tests, 2017-2023
Figure 58 : Global Market for Viral Load Test, 2017-2023
Figure 59 : Gilead Sciences: Antiviral Sales, 2015-2017
Figure 60 : Abbott Laboratories: Revenue Share, by Region, 2017
Figure 61 : Abbott Laboratories: Revenue Share, by Business Segment, 2017
Figure 62 : AbbVie: Revenue Share, by Region, 2016
Figure 63 : Agilent Technologies: Revenue Share, by Region, 2017
Figure 64 : Agilent Technologies: Revenue Share, by Business Segment, 2017
Figure 65 : Becton, Dickinson and Co.: Financial Performance, 2013-2017
Figure 66 : Becton, Dickinson and Co.: Revenue Share, by Business Segment, 2017
Figure 67 : Becton, Dickinson and Co.: Revenue Share, by Region, 2017
Figure 68 : Gilead Sciences: Revenue Share, by Region, 2017
Figure 69 : GlaxoSmithKline: Revenue Share, by Business Segment, 2016
Figure 70 : GlaxoSmithKline: Revenue Share, by Region, 2016
Figure 71 : Johnson & Johnson: Revenue Share, by Business Segment, 2017
Figure 72 : Johnson & Johnson: Revenue Share, by Region, 2017
Figure 73 : Merck & Co.: Revenue Share, by Business Segment, 2016
Figure 74 : Merck & Co.: Revenue Share, by Region, 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report